For that purpose, there has been a concerted effort to develop PET tracers that are sensitive to and ultimately specific to 4R tauopathies, an effort that is complicated by the fact that there is a significantly much lower density of 4R tau pathology in PSP or CBD than the one observed with 3R/4R tau deposits in AD [29]. The gene discussed is MAPT; the disease is Alzheimer disease.